Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium

Rhea-AI Summary

Ambrx Biopharma (NYSE: AMAM) announced its participation in the 2021 San Antonio Breast Cancer Symposium, featuring clinical data from its ACE-Breast-01 and ACE-Breast-03 trials of ARX788. The ACE-Breast-01 trial abstract received a Spotlight Poster Discussion designation, highlighting its significance. Presentations will take place from December 7-10, 2021, with the ACE-Breast-01 spotlight discussion scheduled for December 9 at 7:00 AM CST. Ambrx focuses on developing Engineered Precision Biologics using expanded genetic code technology.

Positive

• ACE-Breast-01 abstract selected for Spotlight Poster Discussion, indicating notable clinical significance.
• Participation in the prestigious San Antonio Breast Cancer Symposium enhances visibility and credibility.

Negative

• None.

- Ambrx’s abstract of the ongoing ACE-Breast-01 clinical trial for ARX788 was selected for a Spotlight Poster Discussion –

SAN DIEGO--(BUSINESS WIRE)-- ​Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), today announced the publication of two abstract poster presentations to be conducted at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is being held from December 7-10, 2021. The abstract poster presentations will highlight clinical data from Ambrx’s ongoing ACE-Breast-03 and ACE-Breast-01 clinical trials of ARX788. The company’s ACE-Breast-01 abstract was selected as a Spotlight Poster Discussion.

All posters will be available virtually on the SABCS website at www.SABCS.org as well as in the symposium poster hall beginning Wednesday, December 8, 2021 at 9:00 AM ET. Details on the abstracts and corresponding poster presentations are shown below.

Poster Number: OT1-02-02
Title: "A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens”
Presentation Time: December 8, 2021 at 5:00 PM CST
Session Name: Ongoing Trials Poster Session 1
Presenters: Sara Hurvitz, MD; Janice Lu, MD; Joy Yan, MD, PhD

Spotlight Poster Discussion Number: PD8-04
Poster Title: “Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01 trial results”
Presentation Time: December 9, 2021 at 7:00 AM CST
Session Name: Spotlight Poster Discussion 8
Presenters: Xichun Hu, MD; Jiang Zhang, MD

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005725/en/

INVESTORS

Laurence Watts

Managing Director

Gilmartin Group, LLC.

619-916-7620

ir@ambrx.com

MEDIA

Ian Stone

Managing Director

Canale Communications

(619) 849-5388

media@ambrx.com

Source: Ambrx, Inc.

FAQ

What is the significance of Ambrx's participation in the 2021 San Antonio Breast Cancer Symposium?

Ambrx's participation highlights its ongoing clinical trials and advancements in cancer treatment, particularly through the presentation of its ACE-Breast-01 trial.

What is the focus of the ACE-Breast-01 trial presented by Ambrx?

The ACE-Breast-01 trial focuses on the safety and anti-tumor activity of ARX788 in patients with HER2-positive metastatic breast cancer.

When will Ambrx present at the San Antonio Breast Cancer Symposium?

Ambrx will present its ACE-Breast-01 trial results during the Spotlight Poster Discussion on December 9, 2021, at 7:00 AM CST.

What is ARX788 and its role in Ambrx's clinical trials?

ARX788 is Ambrx's lead product candidate, aimed at treating HER2-positive metastatic breast cancer patients.

What does a Spotlight Poster Discussion designation mean for Ambrx?

The Spotlight Poster Discussion designation indicates that Ambrx's data is considered significant and of high interest within the scientific community.